Fig. 6From: Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trialsForest plot showing secondary endpoints in overall population in PARP inhibitor arm (case) and chemotherapy/placebo arm in platinum-resistant ovarian cancer (control); A Second progression-free survival (PFS 2); B Time to first subsequent therapy (TFST); C Time to second subsequent therapy (TSST)Back to article page